Post Transplant Lymphoproliferative Disease News and Research

RSS

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus vaccine candidate.

7 Jan 2022

A new therapeutic approach for Epstein-Barr virus-associated tumors

A research team at LKS Faculty of Medicine, The University of Hong Kong (HKUMed) discovered that exosomes derived from Vδ2-T cells (Vδ2-T-Exos) can effectively control Epstein-Barr virus-associated tumours and induce T-cell anti-tumour immunity.

12 Oct 2020

Study suggests combination of MMF and CNIs can protect against rare lymphoma

16 Oct 2015

Researchers link organ transplant drug to rise in rare lymphoma

A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil (MMF) to an increased risk of central nervous system (CNS) lymphoma in solid organ transplant patients. But the same study also found that another class of immunosuppressive drugs, called calcineurin inhibitors (CNIs), given alone or in combination with MMF, appears to protect transplant patients against this rare form of lymphoma.

15 Oct 2015

Single gene found to control growth of some cancers

Research led by Ashok Aiyar, PhD, Associate Professor of Microbiology at LSU Health Sciences Center New Orleans, showing that a single gene can control growth in cancers related to the Epstein-Barr virus and that existing therapeutics can inactivate it, will be published in the June 12, 2009 online issue of PLoS Pathogens.

15 Jun 2009

CellCept linked to reduced cancer incidence

A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.

23 Apr 2004